Solaris Pharma Corporation located Bridgewater, New Jersey announces the final approval from U.S Food and Drug Administration for its Abbreviated New Drug Application for Clindamycin Phosphate Gel USP, 1% (Once-A-Day) in 75 mL bottle a generic version of reference listed drug Clindagel® (clindamycin phosphate) topical gel, 1%. For more updates, please visit the products page or email us directly at info@solaris-pharma.com
News &
Events
Updated: June 2, 2026
Solaris Pharma Receives FDA Approval for Clindamycin Phosphate Gel USP, 1% (Once-A-Day)
About Solaris
Solaris Pharma Corporation, A Privately Held Company Headquartered In Bridgewater, NJ, Is A Specialty Pharmaceutical Company Developing And Commercializing High Value Drug Products With Limited Generic Competitors. Solaris Is Committed To Development Of Complex Dosage Forms And 505(B)(2) Products That Bring Value To Patients By Providing Access To Quality, Affordable Medicine.
Contact
Shalin Jani
CEO
Info@Solaris-Pharma.com
Source: Solaris Pharma Corporation
Press Release
